Pfizer (NYSE:PFE) Releases Earnings Results, Beats Estimates By $0.15 EPS

Pfizer (NYSE:PFE) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.15, MarketWatch Earnings reports. The company had revenue of $14.58 billion for the quarter, compared to analysts’ expectations of $13.41 billion. Pfizer had a return on equity of 24.88% and a net margin of 17.85%. Pfizer’s quarterly revenue was up 44.6% on a year-over-year basis. During the same period last year, the firm earned $0.80 earnings per share. Pfizer updated its FY 2021 guidance to 3.550-3.650 EPS and its FY21 guidance to $3.55-3.65 EPS.

Shares of Pfizer stock remained flat at $$39.83 during trading hours on Tuesday. The stock had a trading volume of 1,788,647 shares, compared to its average volume of 31,749,029. The firm has a 50-day simple moving average of $37.02 and a 200-day simple moving average of $36.78. Pfizer has a twelve month low of $31.61 and a twelve month high of $43.08. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $222.16 billion, a PE ratio of 25.61, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 4th. Stockholders of record on Friday, May 7th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Thursday, May 6th. Pfizer’s payout ratio is currently 52.88%.

Several equities research analysts recently weighed in on the company. Morgan Stanley decreased their target price on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Friday, January 29th. SVB Leerink reduced their price objective on shares of Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a research report on Thursday, April 1st. JPMorgan Chase & Co. set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, February 3rd. DZ Bank reissued a “buy” rating and issued a $41.00 price target on shares of Pfizer in a research report on Wednesday, February 3rd. Finally, Mizuho dropped their price objective on Pfizer from $44.00 to $42.00 and set a “buy” rating on the stock in a report on Wednesday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.47.

A hedge fund recently bought a new stake in Pfizer stock. OLD Mission Capital LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 7,918 shares of the biopharmaceutical company’s stock, valued at approximately $291,000. 67.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Read More: Inverted Yield Curve

Earnings History for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.